Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Chst11em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Chst11em1flox/Cya

Common Name
Chst11-flox
Product ID
S-CKO-12431
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-58250-Chst11-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Chst11-flox Mouse (Catalog S-CKO-12431) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Chst11-flox
Strain ID
CKOCMP-58250-Chst11-B6J-VA
Gene Name
Chst11
Product ID
S-CKO-12431
Gene Alias
C4s, C4ST, C4ST1, C4ST-1, 1110020P09Rik
Background
C57BL/6JCya
Gene Full Name
carbohydrate sulfotransferase 11
Modification
Conditional knockout
NCBI ID
58250 (Mouse)
Phenotype
MGI:1927166
Chromosome
Chr 10 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000040110
NCBI Transcript ID
NM_021439
Target Region
Exon 2
Size of Effective Region
~1.1 kb
Overview of Gene Research
Chst11, or carbohydrate (chondroitin 4) sulfotransferase-11, is a Golgi membrane protein that catalyzes the transfer of sulfate to position 4 of the N-acetylgalactosamine residues of chondroitin. Chondroitin sulfate, whose sulfation is mediated by Chst11, is a predominant proteoglycan in cartilage, playing a crucial role in the developing growth plate of cartilage [5]. It is also involved in various biological processes and diseases through its impact on chondroitin sulfate modification.

Chst11-deficient mouse models have severe chondrodysplasia, congenital arthritis and neonatal lethality, highlighting its crucial role in skeletal morphogenesis [5]. In human studies, a homozygous deletion in CHST11 was found in a consanguineous Pakistani kindred with limb malformations and skeletal defects, further confirming its role in skeletal development [5]. In cancer research, CHST11 is frequently overexpressed in glioblastoma, promoting cell mobility. Targeting CHST11-derived chondroitin 4-sulfate with a specific binding peptide improved the survival rate of orthotopic glioma cell transplant mice [1]. In lung cancer and pulmonary fibrosis, CHST11 levels are elevated, and it contributes to tumor malignancy and fibrotic activator promotion. Analyses suggest the CHST11/integrin axis could be a therapeutic target [2]. In pancreatic cancer, high CHST11 expression correlates with poor prognosis and tumor immune infiltration [3]. In breast cancer, its expression is higher in basal-like and Her2-amplified cell lines, and is controlled by DNA methylation [4]. In clear cell renal cell carcinoma, CHST11 promotes cell proliferation, migration and invasion [6].

In conclusion, Chst11 is essential for skeletal development as demonstrated by animal models. In disease areas, especially cancer, its abnormal expression is associated with tumor progression, immune infiltration and prognosis, making it a potential biomarker and therapeutic target. The study of Chst11 knockout mouse models has provided valuable insights into its function in normal development and disease conditions.

References:
1. Lin, You-Cheng, Chu, Yin-Hung, Liao, Wen-Chieh, Yang, Meng-Yin, Liu, Chiung-Hui. 2023. CHST11-modified chondroitin 4-sulfate as a potential therapeutic target for glioblastoma. In American journal of cancer research, 13, 2998-3012. doi:. https://pubmed.ncbi.nlm.nih.gov/37559985/
2. Li, Chien-Hsiu, Chan, Ming-Hsien, Chang, Yu-Chan, Hsiao, Michael. 2022. The CHST11 gene is linked to lung cancer and pulmonary fibrosis. In The journal of gene medicine, 24, e3451. doi:10.1002/jgm.3451. https://pubmed.ncbi.nlm.nih.gov/36181245/
3. Zhang, Pan, Chen, Dan, Cui, Haimeng, Luo, Qingfeng. . High Expression of CHST11 Correlates with Poor Prognosis and Tumor Immune Infiltration of Pancreatic Cancer. In Clinical laboratory, 68, . doi:10.7754/Clin.Lab.2022.211239. https://pubmed.ncbi.nlm.nih.gov/36546737/
4. Herman, Damir, Leakey, Tatiana I, Behrens, Alice, Kieber-Emmons, Thomas, Monzavi-Karbassi, Behjatolah. 2015. CHST11 gene expression and DNA methylation in breast cancer. In International journal of oncology, 46, 1243-51. doi:10.3892/ijo.2015.2828. https://pubmed.ncbi.nlm.nih.gov/25586191/
5. Shabbir, Rana Muhammad Kamran, Nalbant, Gökhan, Ahmad, Nafees, Malik, Sajid, Tolun, Aslıhan. 2018. Homozygous CHST11 mutation in chondrodysplasia, brachydactyly, overriding digits, clino-symphalangism and synpolydactyly. In Journal of medical genetics, 55, 489-496. doi:10.1136/jmedgenet-2017-105003. https://pubmed.ncbi.nlm.nih.gov/29514872/
6. Hu, Weijing, Chen, Yongquan, Zhang, Lin, Wang, Dongwen, Wu, Bo. 2024. Effect of CHST11, a novel biomarker, on the biological functionalities of clear cell renal cell carcinoma. In Scientific reports, 14, 7704. doi:10.1038/s41598-024-58280-8. https://pubmed.ncbi.nlm.nih.gov/38565604/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research